Antibiotic-resistant Pseudomonas aeruginosa: focus on care in patients receiving assisted ventilation

Area of Science:

• Critical Care Medicine
• Infectious Diseases
• Microbiology

Background:

• Ventilator-associated pneumonia (VAP) caused by Pseudomonas aeruginosa is a significant contributor to ICU morbidity and mortality.
• Increasing antibiotic resistance rates of P. aeruginosa pose a major challenge in managing VAP.
• The emergence of multidrug-resistant (MDR) strains necessitates careful consideration of treatment strategies.

Purpose of the Study:

• To analyze and discuss the choice between combination therapy and monotherapy for empirical treatment of P. aeruginosa VAP.
• To review recommendations from published guidelines regarding VAP management.
• To evaluate the pros and cons of different antibiotic associations and administration routes, including nebulized antibiotics.

Main Methods:

• Review of current literature and published clinical guidelines.
• Analysis of treatment strategies for P. aeruginosa VAP, focusing on empirical settings.
• Discussion of antibiotic resistance patterns and their impact on therapeutic choices.

Main Results:

• The emergence of MDR strains complicates empirical treatment decisions.
• Combination therapy may offer advantages in certain scenarios, while monotherapy might be considered in others, guided by local resistance patterns.
• Nebulized antibiotic administration and extended treatment durations are discussed as potential strategies.

Conclusions:

• Treatment strategies for P. aeruginosa VAP must adapt to rising antibiotic resistance.
• Guideline recommendations for empirical therapy, including combination vs. monotherapy, require careful interpretation.
• Further research on optimal treatment duration and novel administration routes like nebulization is warranted.